Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efprezimod alfa in Severe/Critical COVID-19
NCT04317040Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2020
- Primary completion
- Oct 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of efprezimod alfa in coronavirus disease 2019 (COVID-19), sponsored by Merck & Co.. Started Apr 2020; status: completed.
02
Drugs
efprezimod alfa
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04317040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04317040.